echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Tengshengbo Pharmaceutical for the Treatment of Chronic Hepatitis B Announces the Latest Results of Phase 2 of RNAi Therapy

    Tengshengbo Pharmaceutical for the Treatment of Chronic Hepatitis B Announces the Latest Results of Phase 2 of RNAi Therapy

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 31, Tengsheng Boyao Biotechnology Co.
    , Ltd.
    (hereinafter referred to as "Tengsheng Boyao" or the "Company") announced its clinical stage small interfering ribose at the 31st meeting of the Asia Pacific Association for the Study of the Liver (APASL) in 2022.
    Updated data from a Phase 2 randomized, double-blind, placebo-controlled trial of nucleic acid (siRNA) BRII-835 (VIR-2218) in Chinese patients with chronic hepatitis B virus (HBV) infection, meeting on March 30 It will be held online in Seoul, South Korea from April 3 to April 3

    .

    Data showed a dose-dependent reduction in HBV surface antigen (HBsAg) levels in Chinese patients with chronic HBV infection after two doses of BRII-835 (VIR-2218), and decreased HBsAg levels in both HBeAg-negative and HBeAg-positive patients to a similar degree
    .
    In addition, BRII-835 (VIR-2218) was well tolerated, all treatment-emergent adverse events (TEAEs) were mild or moderate, and no clinically significant increases in alanine aminotransferase (ALT) were observed high

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.